Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249

Article  PubMed  Google Scholar 

El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7):2557–2576

Article  CAS  PubMed  Google Scholar 

Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, Schirmacher P, Vilgrain V (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69(1):182–236. https://doi.org/10.1016/j.jhep.2018.03.019

Article  Google Scholar 

Kudo M, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Tateishi R, Nakashima O, Murakami T, Matsuyama Y et al (2021) Report of the 21st nationwide follow-up survey of primary liver cancer in Japan (2010–2011). Hepatol Res 51(4):355–405

Article  PubMed  Google Scholar 

Guckenberger M, Baus WW, Blanck O, Combs SE, Debus J, Engenhart-Cabillic R, Gauer T, Grosu AL, Schmitt D, Tanadini-Lang S et al (2020) Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery. Strahlenther Onkol 196(5):417–420. https://doi.org/10.1007/s00066-020-01603-1

Article  PubMed  PubMed Central  Google Scholar 

Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393(10185):2051–2058. https://doi.org/10.1016/S0140-6736(18)32487-5

Article  PubMed  Google Scholar 

Gkika E, Adebahr S, Kirste S, Schimek-Jasch T, Wiehle R, Claus R, Wittel U, Nestle U, Baltas D, Grosu AL et al (2017) Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer. Strahlenther Onkol 193(6):433–443. https://doi.org/10.1007/s00066-017-1099-8

Article  CAS  PubMed  Google Scholar 

Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RKS, Dinniwell RE, Kassam Z, Ringash J, Cummings B et al (2013) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 31(13):1631–1639

Article  PubMed  Google Scholar 

Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJM, McRae SE, Widder J, Feng L et al (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16(6):630–637

Article  PubMed  PubMed Central  Google Scholar 

Mohamed AA, Goncalves M, Singh BP, Tometten M, Rashad A, Hölzle F, Hackenberg S, Eble M (2024) Stereotactic radiotherapy in the management of oligometastatic and recurrent head and neck cancer: a single-center experience. Strahlenther Onkol. https://doi.org/10.1007/s00066-023-02180-9

Article  PubMed  Google Scholar 

Hara K, Takeda A, Tsurugai Y, Saigusa Y, Sanuki N, Eriguchi T, Maeda S, Tanaka K, Numata K (2019) Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis. Hepatology. https://doi.org/10.1002/hep.30591

Article  PubMed  Google Scholar 

Kimura T, Aikata H, Takahashi S, Takahashi I, Nishibuchi I, Doi Y, Kenjo M, Murakami Y, Honda Y, Kakizawa H et al (2015) Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. Hepatol Res 45(4):378–386

Article  PubMed  Google Scholar 

Chiang CL, Chan MKH, Yeung CSY, Ho CHM, Lee FAS, Lee VWY, Wong FCS, Blanck O (2019) Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B–C hepatocellular carcinoma. Strahlenther Onkol 195(3):254–264. https://doi.org/10.1007/s00066-018-1391-2

Article  CAS  PubMed  Google Scholar 

Jacob R, Turley F, Redden DT, Saddekni S, Aal AKA, Keene K, Yang E, Zarzour J, Bolus D, Smith JK et al (2015) Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥ 3 cm. https://www.hpbonline.org/article/S1365-182X(15)31172-2/pdf. Accessed 27 July 2019

Shin HS, Hwan Lee S, Jun BG, Kim HS, Kang SH, Park JY, Choi SI, Cheon GJ, Kim YD, Yoo JJ et al (2022) Stereotactic body radiotherapy versus radiofrequency ablation as initial treatment of small hepatocellular carcinoma. Eur J Gastroenterol Hepatol 34(11):1187–1194

Article  CAS  PubMed  Google Scholar 

Wong TCL, Lee VHF, Law ALY, Pang HH, Lam KO, Lau V, Cui TY, Fong ASY, Lee SWM, Wong ECY et al (2021) Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant. Hepatology 74(5):2580

Article  CAS  PubMed  Google Scholar 

Lencioni R, Llovet JM Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. https://doi.org/10.1055/s-0030-1247132. Accessed 4 Jan 2020

Benson R, Madan R, Kilambi R, Chander S (2016) Radiation induced liver disease: a clinical update. J Egypt Natl Canc Inst 28(1):7–11

Article  CAS  PubMed  Google Scholar 

Chapman TR, Bowen SR, Schaub SK, Yeung RH, Kwan SW, Park JO, Yu L, Harris WP, Johnson GE, Liou IW et al (2018) Toward consensus reporting of radiation-induced liver toxicity in the treatment of primary liver malignancies: defining clinically relevant endpoints. Pract Radiat Oncol 8(3):157–166

Article  PubMed  Google Scholar 

Son SH, Jang HS, Lee H, Choi BO, Kang YN, Jang JW, Yoon SK, Kay CS (2013) Determination of the α/β ratio for the normal liver on the basis of radiation-induced hepatic toxicities in patients with hepatocellular carcinoma. Radiat Oncol 8(1):61

Article  PubMed  PubMed Central  Google Scholar 

Lawremce TS, Dworzanin LM, Walker-Andrews SC, Andrews JC, Ten Haken RK, Wollmer IS, Lichter AS, Ensminger WD (1991) Treatment of cancers involving the liver and porta hepatis with external beam irradiation and intraarterial hepatic fluorodeoxyuridine. Int J Radiat Oncol Biol Phys 20(3):555–561

Article  Google Scholar 

Durand-Labrunie J, Baumann A (2020) Curative irradiation treatment of hepatocellular carcinoma: a multicenter phase 2 trial. https://www.sciencedirect.com/science/article/pii/S0360301619345122. Accessed 3 Oct 2023

Il JW, Bae SH, Kim MS, Han CJ, Park SC, Kim SB, Cho EH, Choi CW, Kim KS, Hwang S et al (2020) A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: safety and efficacy. Cancer 126(2):363–372

Article  Google Scholar 

Kimura T, Takeda A, Sanuki N, Ariyoshi K, Yamaguchi T, Imagumbai T, Katoh N, Eriguchi T, Oku Y, Ozawa S et al (2021) Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: the STRSPH study. Hepatol Res 51(4):461–471

Article  PubMed  Google Scholar 

Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, Schipper MJ, Feng M (2016) Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 34(5):452–459. https://doi.org/10.1200/JCO.2015.61.4925

Article  CAS  PubMed  Google Scholar 

Kim N, Cheng J, Jung I, Liang JD, Shih YL, Huang WY, Kimura T, Lee VHF, Zeng ZC, Zhenggan R et al (2020) tereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J Hepatol 73(1):121–129

Article  CAS  PubMed  Google Scholar 

Sapir E, Tao Y, Schipper MJ, Bazzi L, Novelli PM, Devlin P, Owen D, Cuneo KC, Lawrence TS, Parikh ND et al (2018) Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 100(1):122–130

Article  PubMed  Google Scholar 

Méndez Romero A, van der Holt B, Willemssen FEJA, de Man RA, Heijmen BJM, Habraken S, Westerveld H, van Delden OM, Klümpen HJ, Tjwa ETTL et al (2023) Transarterial chemoembolization with drug-eluting beads versus stereotactic body radiation therapy for hepatocellular carcinoma: outcomes from a multicenter, randomized, phase 2 trial (the TRENDY trial). Int J Radiat Oncol Biol Phys 117(1):45–52

Article  PubMed  Google Scholar 

Comito T, Loi M, Franzese C, Clerici E, Franceschini D, Badalamenti M, Teriaca MA, Rimassa L, Pedicini V, Poretti D et al (2022) Stereotactic radiotherapy after incomplete transarterial (chemo-) embolization (TAE\TACE) versus exclusive TAE or TACE for treatment of inoperable HCC: a phase III trial (NCT02323360). Curr Oncol 29(11):8802–8813

Article  PubMed  PubMed Central  Google Scholar 

Brunner TB, Bettinger D, Schultheiss M, Maruschke L, Sturm L, Bartl N, Koundurdjieva I, Kirste S, Neeff HP, Goetz C et al (2021) Efficacy of stereotactic body radiotherapy in patients with hepatocellular carcinoma not suitable for transarterial chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical efficacy study). Front Oncol. https://doi.org/10.3389/fonc.2021.653141

Article  PubMed  PubMed Central  Google Scholar 

Ohri N, Tomé WA, Méndez Romero A, Miften M, Ten Haken RK, Dawson LA, Grimm J, Yorke E, Jackson A (2021) Local control after stereotactic body radiation therapy for liver tumors. Int J Radiat Oncol Biol Phys 110(1):188–195

Article  PubMed  Google Scholar 

Jang WI, Kim MS, Bae SH, Cho CK, Yoo HJ, Seo YS, Kang JK, Kim SY, Lee DH, Han CJ et al (2013) High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol 8(1):1–12. https://doi.org/10.1186/1748-717X-8-250

Article  Google Scholar 

Su TS, Liu QH, Zhu XF, Liang P, Liang SX, Lai L, Zhou Y, Huang Y, Cheng T, Li LQ (2021) Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study. Radiat Oncol 16(1)

Dawson LA, Normolle D, Balter JM, Mcginn CJ, Lawrence TS, Ten Haken RK (2002) Analysis of radiation-induced liver disease using the Lyman NTCP model

Book  Google Scholar 

Li JX, Zhang RJ, Qiu MQ, Yan LY, He ML, Long MY, Zhong JH, Lu HY, Zhou HM, Xiang B‑D et al (2023) Non-classic radiation-induced liver disease after intensity-modulated radiotherapy for Child-Pugh grade B patients with locally advanced hepatocellular carcinoma. Radiat Oncol 18(1):48

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bae S, Park H, Yoon W et al (2019) Treatment outcome after fractionated conformal radiotherapy for hepatocellular carcinoma in patients with Child-Pugh classification B in Korea (KROG 16-05). https://synapse.koreamed.org/articles/1153809. Accessed 6 Oct 2023

Sharma D, Thaper D, Kamal R, Yadav HP (2023) Role of palliative SBRT in barcelona clinic liver cancer-stage C hepatocellular carcinoma patients. Strahlenther Onkol 199(9):838–846. https://doi.org/10.1007/s00066-023-02065-x

Article  PubMed  Google Scholar 

Dawson LA, Winter KA, Knox JJ et al (2023) NRG